Back to search results
NCT05887492

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Tango Therapeutics, Inc.
~126 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:TNG260Pembrolizumab

At a glance

Recruiting sites
0 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determine the MTD and RP2D(s) (Phase 1 only)
Measured over 42 days
+1 more outcome measured

Conditions

Non Small Cell Lung Cancer
Solid Tumors, Adult
Lung Cancer
Lung Adenocarcinoma

Explore related trials

Lung Non-Small Cell CarcinomaSolid NeoplasmSTK11 Gene

NCT05887492

Where you'd take part

This study runs at 13 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Dana Farber Cancer Institute

    Boston, Massachusettsno site contact published

  • Florida Cancer Specialists

    Sarasota, Floridano site contact published

  • Henry Ford Health System

    Detroit, Michiganno site contact published

  • New York University Langone Health

    New York, New Yorkno site contact published

  • NEXT Oncology Virginia

    Fairfax, Virginiano site contact published

  • NYU Langone Hematology Oncology Associates-Mineola

    Mineola, New Yorkno site contact published

  • Sarah Cannon Tennessee Oncology

    Nashville, Tennesseeno site contact published

  • SCRI at HealthOne

    Denver, Coloradono site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Adam Crystal, MD, PhD · STUDY_DIRECTOR · Tango Therapeutics, Inc.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is ≥18 years of age at the time of signature of the main study ICF.
Has ECOG performance status of 0 or 1.
Has measurable disease based on RECIST v1.1.
All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method
Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor.
Adequate organ function/reserve per local labs
Adequate liver function per local labs
Adequate renal function per local labs
Negative serum pregnancy test result at screening
Written informed consent must be obtained according to local guidelines

Exclusion

Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients
Uncontrolled intercurrent illness that will limit compliance with the study requirements
Active infection requiring systemic therapy
Currently participating in or has planned participation in a study of another investigational agent or device
Impairment of GI function or disease that may significantly alter the absorption of oral TNG260
Active prior or concurrent malignancy.
Central nervous system metastases associated with progressive neurological symptoms
Current active liver disease from any cause
Clinically relevant cardiovascular disease
A female patient who is pregnant or lactating

What this trial measures

  • Determine the MTD and RP2D(s) (Phase 1 only)42 days

    To determine the MTD and RP2D(s) of TNG260 when administered in combination with pembrolizumab

  • Measure antitumor activity using RECIST 1.1 (Phase 2 only)12 weeks

    To assess antineoplastic activity of TNG260 when administered in combination with pembrolizumab in participants with locally advanced unresectable or metastatic STK11-mutated solid tumors by measuring ORR, DOR, and PFS by RECIST 1.1